Chemical Compound Review:
Levitra 3-[2-ethoxy-5-(4- ethylpiperazin-1...
Synonyms:
Vivanza, Vardenafil, CHEMBL1520, SureCN5772, Levitra (TN), ...
Martin-Morales,
Meijide,
García,
Artes,
Muñoz,
Hatzichristou,
Aliotta,
Auerbach,
Barkin,
Lording,
Murdock,
Wilkins,
McBride,
Colopy,
Carson,
Wensing,
Bauer,
Unger,
Rohde,
Heinig,
Rosen,
Shabsigh,
Berber,
Assalian,
Menza,
Rodriguez-Vela,
Porto,
Bangerter,
Seger,
Montorsi,
Fleshner,
Harvey,
Adomat,
Wood,
Eberding,
Hersey,
Guns,
Foresta,
Caretta,
Lana,
De Toni,
Biagioli,
Vinanzi,
Ferlin,
Kloner,
Jackson,
Emmick,
Mitchell,
Bedding,
Warner,
Pereira,
Gratz,
Gamble,
Flurer,
Saenz de Tejada,
Angulo,
Cuevas,
Fernández,
Moncada,
Allona,
Lledó,
Körschen,
Niewöhner,
Haning,
Pages,
Bischoff,
Thadani,
Smith,
Nash,
Bittar,
Glasser,
Narayan,
Stein,
Larkin,
Mazzu,
Tota,
Pomerantz,
Sundaresan,
Basu,
Ryder,
- Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Sarfati, M., Mateo, V., Baudet, S., Rubio, M., Fernandez, C., Davi, F., Binet, J.L., Delic, J., Merle-Beral, H. Blood (2003)
- Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S.H., Corbin, J.D., Robinson, H., Xin, Z., Lin, G., Ke, H. J. Biol. Chem. (2006)
- Vardenafil: a review of its use in erectile dysfunction. Keating, G.M., Scott, L.J. Drugs (2003)
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. Salloum, F.N., Takenoshita, Y., Ockaili, R.A., Daoud, V.P., Chou, E., Yoshida, K., Kukreja, R.C. J. Mol. Cell. Cardiol. (2007)
- Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Bender, A.T., Beavo, J.A. Pharmacol. Rev. (2006)
- Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. Martin-Morales, A., Meijide, F., García, N., Artes, M., Muñoz, A. The journal of sexual medicine (2007)
- Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Hellstrom, W.J., Gittelman, M., Karlin, G., Segerson, T., Thibonnier, M., Taylor, T., Padma-Nathan, H. Urology (2003)
- Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. Zoraghi, R., Corbin, J.D., Francis, S.H. J. Biol. Chem. (2006)
- Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Caglayan, E., Huntgeburth, M., Karasch, T., Weihrauch, J., Hunzelmann, N., Krieg, T., Erdmann, E., Rosenkranz, S. Arch. Intern. Med. (2006)
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Ghofrani, H.A., Voswinckel, R., Reichenberger, F., Olschewski, H., Haredza, P., Karadaş, B., Schermuly, R.T., Weissmann, N., Seeger, W., Grimminger, F. J. Am. Coll. Cardiol. (2004)
- The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. Thadani, U., Smith, W., Nash, S., Bittar, N., Glasser, S., Narayan, P., Stein, R.A., Larkin, S., Mazzu, A., Tota, R., Pomerantz, K., Sundaresan, P. J. Am. Coll. Cardiol. (2002)
- Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. Kloner, R.A., Jackson, G., Emmick, J.T., Mitchell, M.I., Bedding, A., Warner, M.R., Pereira, A. J. Urol. (2004)
- Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. Hatzichristou, D.G., Aliotta, P., Auerbach, S., Barkin, J., Lording, D., Murdock, M., Wilkins, H.J., McBride, T.A., Colopy, M.W., Carson, C.C. Clinical therapeutics. (2005)
- Vardenafil reverses erectile dysfunction induced by paroxetine in rats. Angulo, J., Bischoff, E., Gabancho, S., Cuevas, P., Sáenz de Tejada, I. Int. J. Impot. Res. (2003)
- Vardenafil increases coronary flow response to hypercapnic acidosis in isolated guinea pig heart. Brand, M., Deussen, A. Basic Res. Cardiol. (2007)
- Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Blount, M.A., Beasley, A., Zoraghi, R., Sekhar, K.R., Bessay, E.P., Francis, S.H., Corbin, J.D. Mol. Pharmacol. (2004)
- A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization. Blount, M.A., Zoraghi, R., Ke, H., Bessay, E.P., Corbin, J.D., Francis, S.H. Mol. Pharmacol. (2006)
- New treatment options for erectile dysfunction in patients with diabetes mellitus. Basu, A., Ryder, R.E. Drugs (2004)
- Relationship Between Vascular Damage Degrees and Endothelial Progenitor Cells in Patients with Erectile Dysfunction: Effect of Vardenafil Administration and PDE5 Expression in the Bone Marrow. Foresta, C., Caretta, N., Lana, A., De Toni, L., Biagioli, A., Vinanzi, C., Ferlin, A. Eur. Urol. (2007)
- The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Saenz de Tejada, I., Angulo, J., Cuevas, P., Fernández, A., Moncada, I., Allona, A., Lledó, E., Körschen, H.G., Niewöhner, U., Haning, H., Pages, E., Bischoff, E. Int. J. Impot. Res. (2001)
- Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices. Gratz, S.R., Gamble, B.M., Flurer, R.A. Rapid Commun. Mass Spectrom. (2006)
- Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. Rajagopalan, P., Mazzu, A., Xia, C., Dawkins, R., Sundaresan, P. Journal of clinical pharmacology. (2003)
- Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in healthy male subjects. Wensing, G., Bauer, R., Unger, S., Rohde, G., Heinig, R. International journal of clinical pharmacology and therapeutics. (2006)
- Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. Werkström, V., Svensson, A., Andersson, K.E., Hedlund, P. BJU Int. (2006)
- Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Mulhall, J.P., Montorsi, F. Eur. Urol. (2006)
- Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Rosen, R., Shabsigh, R., Berber, M., Assalian, P., Menza, M., Rodriguez-Vela, L., Porto, R., Bangerter, K., Seger, M., Montorsi, F. The American journal of psychiatry. (2006)
- The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. Bischoff, E., Niewoehner, U., Haning, H., Es Sayed, M., Schenke, T., Schlemmer, K.H. J. Urol. (2001)
- Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. Fleshner, N., Harvey, M., Adomat, H., Wood, C., Eberding, A., Hersey, K., Guns, E. J. Urol. (2005)
- Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Stark, S., Sachse, R., Liedl, T., Hensen, J., Rohde, G., Wensing, G., Horstmann, R., Schrott, K.M. Eur. Urol. (2001)